Icotrokinra

Chemical formula: C₉₀H₁₂₀N₂₀O₂₂S₂  Molecular mass: 1,896.833 g/mol  PubChem compound: 162462321

Mechanism of action

Icotrokinra is a peptide that binds selectively to the IL-23 receptor (IL-23R) with high affinity and competitively antagonizes the binding of IL-23. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses, but when produced in excess contributes to chronic inflammation associated with plaque psoriasis. Icotrokinra inhibits the IL-23/IL-23R-dependent release of proinflammatory cytokines.

Pharmacodynamic properties

In evaluated patients with plaque psoriasis serum levels of IL-17A, IL-17F, IL-22, β-defensin-2 and IL-19 were reduced after treatment with icotrokinra. Gene expression levels of IL-17A, IL-17F, IL-22, DEFB4A and IL-19 in psoriatic skin, were normalised to non-lesional skin. Reductions in epidermal thickness and densities of T cells, including CD8+ tissue resident memory T cells, were also observed.

Pharmacokinetic properties

Absorption

Icotrokinra is a compound with low solubility and low permeability.

The median (range) Tmax of icotrokinra after oral administration is 2.00 (0.25-8.00) hours in healthy subjects. The mean Cmax and mean AUC∞ of icotrokinra were 3.62 ng/mL and 44.8 ng.h/mL, respectively.

After repeat once daily dosing of icotrokinra, steady-state icotrokinra is expected within 3 days with minimal accumulation, consistent with its terminal half-life.

Inter-subject variability of Cmax and AUC∞ was estimated to be 26.7% and 19.6%, respectively. Intra-subject variability of Cmax and AUC∞ was estimated to be 35.6% and 20.7%, respectively.

Based on nonclinical data, the absolute bioavailability of icotrokinra was <1%.

Food effect

In healthy subjects, co-administration of a single icotrokinra 200 mg dose orally with a high-calorie, high-fat meal decreased icotrokinra AUC∞ and Cmax by 43% and 59%, respectively, relative to fasted state. Icotrokinra should be taken upon waking at least 30 minutes before eating food.

Oral administration of a single icotrokinra 200 mg tablet with caffeine resulted in no difference in exposure.

Co-administration of a single icotrokinra 200 mg tablet orally with whole milk decreased Cmax by 33% and AUC∞ by 24% compared with co-administration with water.

Distribution

Icotrokinra is 52% bound to plasma protein. Blood to plasma partition ratio was 0.53. The volume of distribution (V/F) at steady state is 92 800 L.

Biotransformation

Icotrokinra is a peptide, and intact active substance is the main medicine-related species in plasma. Icotrokinra is metabolised by peptide catabolism into smaller peptides and is not metabolised by CYP enzymes.

Elimination

The median terminal half-life (t1/2) of icotrokinra is 12 hours. Clearance following oral dosing (Cl/F) is 6 550 L/h.

The majority of the active substance is not absorbed with 37% to 81% of the intact medicine recovered unchanged in faeces up to 24 hours after oral dosing of 10 to 1 000 mg. Less than 0.001% of administered dose was recovered as intact medicine in urine.

Renal clearance is the main route of elimination for the absorbed medicine.

Linearity

Following oral administration, icotrokinra Cmax and AUC increased in an almost dose-proportional manner over a dose range of 10 to 1 000 mg (approximately 0.05 to 5 times the recommended dose) in healthy subjects.

Immunogenicity

Among icotrokinra-treated patients who developed anti-drug antibodies, population pharmacokinetic analysis using pooled data from the four Phase III clinical studies through Week 52 showed that Cmax and AUC increased by 1.2- and 1.3-fold respectively, compared with patients who did not develop anti-drug antibodies.

There was no identified clinically significant effect of anti-drug antibodies on pharmacokinetics, safety or effectiveness of icotrokinra through Week 52.

Special populations

Based on population pharmacokinetic analysis, age (12-87 years), sex, race, ethnicity, do not have a clinically meaningful effect on the pharmacokinetics of icotrokinra.

Body weight

Clearance and volume of distribution of icotrokinra after oral dosing increased with increasing body weight (39-211 kg). These differences are not clinically meaningful, and no dose adjustment is warranted.

Paediatric population (12 years to less than 18 years of age)

No meaningful difference in the systemic exposure of icotrokinra was observed in paediatric patients with plaque psoriasis 12 years of age and older weighing at least 40 kg compared to adults.

Elderly

In the population pharmacokinetic analysis, age did not have a significant impact on the pharmacokinetics of icotrokinra.

Renal impairment

Icotrokinra AUC∞ increased 2.47-fold and 2.78-fold in patients with moderate renal impairment (eGFR ≥30 to <60 mL/min) and severe renal impairment (eGFR ≥15 to <30 mL/min), respectively, compared to patients with normal renal function (eGFR ≥90 mL/min). Mild renal impairment (eGFR ≥60 to <90 mL/min) had no effect on icotrokinra exposure based on population pharmacokinetic analysis. Patients with end-stage renal disease (eGFR <15 mL/min) or patients on dialysis were not studied.

Icotrokinra Cmax increased 1.79-fold and 1.27-fold in patients with moderate renal impairment (eGFR ≥30 to <60 mL/min) and severe renal impairment (eGFR ≥15 to <30 mL/min), respectively, compared to patients with normal renal function (eGFR ≥90 mL/min).

Hepatic impairment

No formal pharmacokinetic studies with icotrokinra were conducted in patients with hepatic impairment. Changes in hepatic function are unlikely to have any effect on the elimination of icotrokinra as icotrokinra is not metabolised through hepatic pathways.

Preclinical safety data

Nonclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenicity, and toxicity to reproduction and development.

Icotrokinra was neither embryo-lethal nor teratogenic in rats or rabbits at maternal exposures at least 95 times the maximum recommended human dose (MRHD), respectively based on unbound AUC. In rabbits, maternal body weight loss, low food consumption, and pregnancy losses were observed at maternal exposures 95 times the MRHD based on unbound AUC.

Icotrokinra had no effects on prenatal and post-natal development in rats at maternal exposures 127 times the MRHD based on total AUC. Although not directly measured in rat milk, icotrokinra was detected in the plasma of nursing rat pups. On post-natal day 12, the mean pup-to-maternal plasma ratio for icotrokinra was 0.042 to 0.29.

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈